OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Status:	Completed
Conditions:	Lung Cancer, Lung Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	1/12/2018
Start Date:	November 1, 2001
End Date:	January 30, 2004

A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease

The purpose of this study is to determine if OSI-774 will improve overall survival of
patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of
care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor
receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the
U.S. Food and Drug Administration (FDA).

- Clinical diagnosis of stage IIIB or IV non-small cell lung cancer.

- Must have evidence of disease (clinical or radiological).

- Have failed 1 but no more than 2 prior chemotherapy regimens, have recovered from any
side effects and have not had any chemotherapy for at least 21 days.

- If the patient has had surgery, the surgery was at least 2 weeks ago.

- Patients whose cancer has spread to their brain or central nervous system are
eligible, providing that they have been on stable dose of steroids for at least 4
weeks and are free of symptoms.

- If the patient received radiation therapy, treatment was at least 4 weeks ago.

We found this trial at

sites

Centro Medico Confidence

Buenos Aires, CP

from

Buenos Aires,